There was much excitement when the FDA approved a new drug called Aduhelm to treat patients with Alzheimer’s disease.  Although there was some debate over its efficacy, the fact that there have been no new drugs brought to market to treat this horrible disease in decades had some filled with hope.  However, Biogen Inc., the pharmaceutical company who makes the drug, admitted this week that there was one death linked to Aduhelm.  The company announced that a 75-year old who took the drug was hospitalized and diagnosed with swelling in the brain before dying.  It’s unclear that the brain swelling was linked to the drug, however, there is sure to be an investigation due to the fact that brain swelling, also known as ARIA-E, was cited as one of the most common side effects during testing of the drug.

 

https://www.wsj.com/articles/biogen-investigates-death-of-aduhelm-patient-11636479862

Recommended Posts